What Are GLP-1 Medications, and Why Does Your Body Have a Receptor for Them?

When a patient asks me about Ozempic, they almost always phrase it as a weight-loss drug. That framing is understandable — it's how these medications have entered public consciousness. But it misses what's actually interesting about them, and it misses why a single injection per week can simultaneously lower your blood sugar, reduce your risk of heart attack, protect your kidneys, calm your liver, and ease your knee pain.

These medications work because they mimic hormones your gut already makes. Your body already has the infrastructure. GLP-1 drugs are, in a sense, a pharmaceutical amplification of a signaling system that evolved to coordinate metabolic health across multiple organ systems at once.

Let me explain how that works — starting with the hormone itself.

The Hormone Your Gut Makes After Every Meal

When you eat, specialized cells lining your small intestine — called L-cells — release a peptide called glucagon-like peptide-1 (GLP-1). This happens within minutes of food entering your gut, even before nutrients are fully absorbed. GLP-1 is what's called an incretin hormone: a gut-derived signal that travels in the bloodstream and tells other organs that food has arrived and metabolism needs to shift accordingly.

The problem with your body's natural GLP-1 is that it degrades extremely fast. An enzyme called dipeptidyl peptidase-4 (DPP-4) breaks it down within one to two minutes of secretion. So while your gut releases GLP-1 after every meal, the signal is brief and local. Your body uses it, then it's gone.

GLP-1 receptor agonists — the drug class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are engineered to do the same thing GLP-1 does, but without being destroyed by DPP-4. Semaglutide, for example, has a half-life of about one week, which is why it can be injected just once weekly and still maintain a steady signal throughout your body.

Tirzepatide: Two Hormones, One Injection

Semaglutide works exclusively at the GLP-1 receptor. Tirzepatide, approved more recently, is what's called a dual agonist: it activates both the GLP-1 receptor and a second receptor — the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP is another incretin released by K-cells in the duodenum after eating, and it works in synergy with GLP-1 to regulate insulin, glucagon, and fat storage.

The combination appears to be additive — and in some respects more than additive. Head-to-head trials consistently show tirzepatide outperforming semaglutide on both blood sugar reduction and weight loss. I'll cover the efficacy numbers in detail in Post 3. For now, what matters conceptually is that tirzepatide is operating on two separate metabolic signaling pathways simultaneously.

Where GLP-1 Receptors Are Found — and Why It Matters

The GLP-1 receptor is not just in the pancreas. It's expressed in the brain, heart, blood vessels, kidneys, liver, gut, and joints. This is why a drug designed to lower blood sugar turned out to also reduce heart attacks, slow kidney disease, help with liver inflammation, ease arthritis pain, and reduce cravings for alcohol and drugs. The drug goes where the receptor is.

Here's a quick map of the organ systems where the evidence is strongest:

How GLP-1 Drugs Work in the Brain: Appetite Is Not Just Willpower

This is the part I think is most important for patients to understand, because it directly addresses the stigma around obesity and weight-loss medication.

Your brain has a sophisticated system for regulating food intake — centered in a region called the hypothalamus, specifically in circuits of neurons that release appetite-stimulating signals (neuropeptide Y, AgRP) and appetite-suppressing signals (POMC, CART). GLP-1 receptors sit in the middle of this circuitry. When GLP-1 binds there, it shifts the balance toward satiety — the feeling of having had enough.

But GLP-1 also acts on the brain's reward circuitry: the nucleus accumbens and the mesolimbic dopamine system — the same system that drives cravings for food, alcohol, nicotine, and other substances. This is why many patients on semaglutide report a dramatic reduction in "food noise" — the constant mental preoccupation with eating. And it's why this same brain pathway appears to underlie the emerging evidence that GLP-1 drugs reduce alcohol and drug cravings (which I'll address separately).

The point is this: obesity is not a failure of willpower. But I want to go further than that, because I think the willpower framing misunderstands the problem at a much deeper level than just brain chemistry.

For most of human history, starvation was a routine part of life. Food was scarce, calorie-dense meals were rare, and survival depended on eating aggressively when food was available and storing that energy as body fat against the next period of scarcity. The human body is exquisitely well-designed for that environment. Our hunger drives are powerful, our fat storage mechanisms are efficient, and our brains are wired to treat calorie-dense food as a reward worth pursuing. These are not design flaws. They are survival features — features that kept our ancestors alive through famines, droughts, and winters.

The problem is that our environment has changed dramatically faster than evolution can track. We now live surrounded by hyper-palatable, calorie-dense, heavily engineered food available at any hour, requiring essentially no physical effort to obtain. The same survival instincts that protected people for millennia now drive overconsumption in an environment those instincts were never designed to navigate. Obesity is, in large part, a mismatch between ancient biology and a modern food environment — not a character failure.

GLP-1 drugs are not giving patients willpower they didn't have. They're correcting a physiological signal that was overwhelmed by an environment it wasn't built for.

How GLP-1 Drugs Work in the Pancreas: Smart Insulin Secretion

In the pancreas, GLP-1 receptor activation stimulates beta cells to release insulin — but only when blood glucose is elevated. This is fundamentally different from older diabetes drugs like sulfonylureas, which push insulin release regardless of blood sugar level, risking dangerous drops in blood glucose (hypoglycemia). GLP-1 drugs have a built-in safety mechanism: when your blood sugar is normal or low, the signal quiets automatically.

Simultaneously, GLP-1 suppresses glucagon — a hormone released by pancreatic alpha cells that tells the liver to dump stored glucose into the bloodstream. Elevated glucagon is a major driver of high fasting blood sugar in type 2 diabetes. Blocking it is half the mechanism by which these drugs lower blood sugar.

How GLP-1 Drugs Work in the Gut: Slowing the Pipeline

GLP-1 slows gastric emptying — the rate at which food moves from your stomach into your small intestine. A slower transit means a slower rise in blood sugar after meals, and it prolongs the feeling of fullness after eating.

This effect is real and clinically meaningful. It's also responsible for some of the most common side effects: nausea, vomiting, bloating, and constipation, particularly in the early weeks of treatment when the dose is being increased. Slowing escalation reduces these symptoms considerably. I'll address this in detail in Post 2.

How GLP-1 Drugs Work in the Heart and Blood Vessels

The cardiovascular benefits of GLP-1 medications are among the most exciting findings in the field, and they appear to operate through multiple mechanisms simultaneously.

GLP-1 receptors are expressed directly in the heart muscle (myocardium) and in the inner lining of blood vessels (endothelium). Activation there reduces inflammation in the artery wall — specifically, it dampens the macrophage-driven inflammatory process that makes atherosclerotic plaques unstable and prone to rupture. It also appears to improve the ability of the endothelium to regulate blood flow, reduces blood pressure modestly, and lowers LDL cholesterol and triglycerides.

How GLP-1 Drugs Work in the Kidneys

The kidney's filtering units — the glomeruli — are under constant pressure and inflammatory stress in patients with diabetes and obesity. GLP-1 receptors are expressed in the kidney's tubular cells, and activation there appears to reduce oxidative stress and inflammation directly, while the weight loss and blood pressure reduction from GLP-1 therapy further reduce mechanical stress on the kidney's filtering membranes.

How GLP-1 Drugs Work in the Liver

Fatty liver disease — now more precisely called metabolic dysfunction-associated steatohepatitis, or MASH — occurs when excess fat accumulates inside liver cells and triggers an inflammatory cascade that can progress to fibrosis (scarring) and eventually cirrhosis. GLP-1 receptors in liver and fat cells appear to reduce both fat accumulation and the inflammatory response. The weight loss that accompanies GLP-1 therapy also directly reduces the metabolic stress driving liver fat deposition.

I want to pause here and say something important about the context: MASH is extraordinarily common — affecting an estimated 5% of the global population — and until very recently, we had essentially no FDA-approved pharmacological treatments for it. The standard of care was lifestyle modification, weight loss, and management of underlying metabolic disease. Resmetiron (a thyroid hormone receptor beta agonist) received FDA approval for noncirrhotic MASH in 2024 and represented the first drug approval for this indication. GLP-1 medications are now the second class to achieve that bar. For a disease this prevalent and this serious, having two effective pharmacological options is genuinely new territory.

How GLP-1 Drugs Work in the Joints

The knee osteoarthritis data surprised many in the field, because the benefit appeared to exceed what you'd expect from weight loss alone. GLP-1 receptors are expressed in cartilage cells (chondrocytes), and laboratory research suggests that GLP-1 activates metabolic protective pathways within those cells — reducing the inflammatory breakdown of cartilage independent of body weight.

What This Series Covers Next

Now that you understand the mechanism — why these drugs work across so many systems — the remaining posts in this series go deeper on each of the questions patients most often ask me:

• Post 2 covers long-term safety and side effects — including what we know, what we don't, and which patients need extra caution.
• Post 3 compares GLP-1 weight loss efficacy to bariatric surgery and lifestyle modification, with honest numbers.
• Post 4 covers what happens when you combine GLP-1 therapy with structured exercise and dietary changes — and why that combination outperforms either alone.
• Post 5 addresses the compounding pharmacy question directly: what's in those cheaper versions, whether they're safe, and how to evaluate whether your source is legitimate.
• Post 6 covers GLP-1 medications and reproductive health, including fertility restoration in women with PCOS, what we know about pregnancy safety, and the "Ozempic babies" phenomenon.